早发型阿尔茨海默病与低密度脂蛋白胆固醇升高及APOB罕见编码变异的相关性
该病例系列研究在267份样本中直接测定血浆胆固醇,发现控制APOE E4后早发型阿尔茨海默病(EOAD)患者的总胆固醇、LDL-C和ApoB水平均高于对照;对2125份样本测序显示EOAD病例中APOB罕见编码变异显著富集,提示LDL-C在EOAD发病中起重要作用。
要点
- 控制APOE E4后,EOAD患者LDL-C平均比对照高22.0 mg/dL(P=1.8×10⁻⁶)。
- EOAD病例中APOB罕见编码变异显著富集(效应量0.20,P=4.20×10⁻⁴)。
- APOE E4仅解释EOAD变异的10.1%,提示其他遗传因素参与。
核心结论
- LDL-C升高与EOAD患病概率增高相关。
- EOAD病例中APOB罕见编码变异富集,APOB编码LDL-C的主要蛋白。
- LDL-C在EOAD发病机制中起重要作用,APOB变异与AD风险存在直接联系。
研究设计与样本
- 病例系列研究,直接测定267份来自Emory大学和加州大学旧金山分校AD研究中心的血浆胆固醇样本。
- 对2125例来自29个AD研究中心的EOAD病例和对照进行APOB、APP、PSEN1和PSEN2测序。
- 采用多元线性回归分析胆固醇与EOAD的关联。
主要发现
- 2125份测序样本中1276份来自女性(60.0%),654份来自EOAD患者(30.8%)。
- EOAD病例平均年龄55.6(4.3)岁,对照平均年龄72.0(9.6)岁。
- APOE E4解释EOAD变异的10.1%。
- 控制APOE E4后,EOAD病例总胆固醇平均差21.9(5.2)mg/dL(P=2.9×10⁻⁵),LDL-C平均差22.0(4.5)mg/dL(P=1.8×10⁻⁶),ApoB平均差12.0(2.4)mg/dL(P=2.0×10⁻⁶)。
- 约3%的EOAD病例携带已知AD致病突变。
临床怎么用
- 对早发型阿尔茨海默病患者或高危人群,可关注血浆LDL-C和ApoB水平。
- APOB罕见编码变异可能作为EOAD遗传风险评估的候选标记。
局限性
- 研究为病例系列设计,未明确报告盲法或混杂因素控制细节。
- 胆固醇直接测定仅基于267份冻结样本,样本量有限。
- 约3%的EOAD病例携带已知致病突变,多数病例遗传背景仍未明确。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Early-onset Alzheimer disease (EOAD) is a rare form of Alzheimer disease (AD) with a large genetic basis that is only partially understood. In late-onset AD, elevated circulating cholesterol levels increase AD risk even after adjusting for the apolipoprotein E ε4 (APOE E4) allele, a major genetic factor for AD and elevated cholesterol levels; however, the role of circulating cholesterol levels in EOAD is unclear. OBJECTIVES: To investigate the association between circulating cholesterol levels and EOAD and to identify genetic variants underlying this possible association. DESIGN, SETTING, AND PARTICIPANTS: In this case series, plasma cholesterol levels were directly measured in 267 samples from the AD research centers (ADRCs) of Emory University and University of California, San Francisco, collected from January 21, 2009, through August 21, 2014. The association between cholesterol and EOAD was examined using multiple linear regression. To determine the underlying genetic variants, APOB, APP, PSEN1, and PSEN2 were sequenced in samples from 2125 EOAD cases and controls recruited from 29 ADRCs from January 1, 1984, through December 31, 2015. Data were analyzed from November 23, 2016, through April 10, 2018. EXPOSURES: Clinical diagnosis, age at clinical diagnosis, plasma cholesterol measures (total cholesterol, low-density lipoprotein cholesterol [LDL-C], high-density lipoprotein cholesterol, triglycerides, and apolipoprotein B), and genetic variants in APOE, APP, PSEN1, PSEN2, and APOB. MAIN OUTCOMES AND MEASURES: The primary outcome was the association between EOAD and plasma cholesterol measures. The secondary outcome was the association between EOAD and the burden of genetic variants in APOB. RESULTS: Of the 2125 samples that underwent genetic sequencing, 1276 were from women (60.0%) and 654 (30.8%) were from patients with EOAD (mean [SD] ages, 55.6 [4.3] years for cases and 72.0 [9.6] years for controls). APOE E4 explained 10.1% of the variance of EOAD. After controlling for APOE E4, EOAD cases had higher levels of total cholesterol (mean difference [SE], 21.9 [5.2] mg/dL; P = 2.9 × 10-5), LDL-C (mean difference [SE], 22.0 [4.5] mg/dL; P = 1.8 × 10-6), and ApoB (mean difference [SE], 12.0 [2.4] mg/dL; P = 2.0 × 10-6) than controls in 267 frozen samples. Approximately 3% of EOAD cases carried known AD-causing mutations. Gene-based rare variant burden testing in 2066 samples showed that rare APOB coding variants were significantly more abundant in EOAD cases after adjusting for sex, APOE E4, genetic principal components, ADRC center, and batch (effect size, 0.20; P = 4.20 × 10-4). CONCLUSIONS AND RELEVANCE: Elevated LDL-C levels were associated with higher probability of having EOAD, and EOAD cases were enriched for rare coding variants in APOB, which codes for the major protein of LDL-C. Collectively, these novel findings highlight the important role of LDL-C in EOAD pathogenesis and suggest a direct link of APOB variants to AD risk.
引用
- Wingo TS, Cutler DJ, Wingo AP, et al. Association of Early-Onset Alzheimer Disease With Elevated Low-Density Lipoprotein Cholesterol Levels and Rare Genetic Coding Variants of APOB. JAMA Neurol. 2019. PMID: 31135820. doi:10.1001/jamaneurol.2019.0648
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。